GENFLEET-B(02595): The subject, products, and disputed issues related to the letter issued by Rev Med have nothing to do with the company.

GENFLEET-B (02595) issued an announcement, noting recent reports involving Revolution Medicines Inc. ("RevMed") sending letters to third-party companies regarding disputes over RAS inhibitor patents and commercial secrets. The company hereby clarifies and emphasizes that the subjects, products, and disputes mentioned in the letters sent by RevMed are not related to the company. The company's Pan RAS inhibitor GFH276 has fully independent and original intellectual property rights, and there is no similar risk of infringement or commercial secret disputes. The company has established a comprehensive global patent layout for the Pan RAS inhibitor project, and patents covering the compound structure of GFH276 were officially published on March 6, 2025. The patent protection period is expected to extend until 2044.